Biocon’s Oral Insulin Gains Momentum With JDRF Backing

Biocon’s oral insulin program has received a boost with the US-based JDRF supporting plans to progress its drug candidate in type 1 diabetes. While the pullback of players like Novo Nordisk underscores the potential risks in the oral insulin space, JDRF says early results of Biocon’s candidate “warrant support” for further studies.

JDRF, a global organization funding type 1 diabetes (T1D) research and advocacy worldwide, plans to provide financial support to progress Biocon Ltd.’s novel oral insulin drug candidate, insulin Tregopil, for type 1 diabetes (T1D).

JDRF (or the Juvenile Diabetes Research Foundation as it was known) will support a global multiple ascending dose study with...